UPenn Team Develops sEV-Powered Cancer-Fighting Strategy

Researchers at the University of Pennsylvania's Perelman School of Medicine have developed an innovative approach to cancer treatment using small extracellular vesicles (sEVs). This new method, which targets the death receptor 5 (DR5) on cancer cells, has shown significant potential in preclinical studies against multiple cancer types.

The study, published in Science Advances, details how the team engineered sEVs from human cells to target DR5, a receptor that can trigger cell death when activated. This approach builds on a decades-old anticancer strategy but offers several advantages over previous methods.

In laboratory tests, the engineered sEVs effectively killed various cancer cell types and outperformed DR5-targeting antibodies, which have been a leading strategy in this field. The sEVs also demonstrated impressive results in mouse models, inhibiting tumor growth and significantly extending survival rates compared to antibody treatments.

Xiaowei "George" Xu, the study's senior author, explained, "This new strategy has a number of advantages compared to previous DR5-targeting strategies and other anticancer immunotherapies, and after these encouraging preclinical results, we're developing it further for human clinical trials."

The researchers used sEVs derived from natural killer (NK) cells, which are known for their cancer-fighting properties. These sEVs were engineered to carry an antibody fragment that strongly binds to and activates DR5. The study found that the sEVs not only attacked cancer cells but also targeted cancer-associated fibroblasts and myeloid-derived suppressor cells, potentially disrupting the immunosuppressive environment around tumors.

This approach shows promise for treating solid tumors, where the hostile microenvironment has challenged many forms of immunotherapy. Additionally, sEVs offer potential advantages in manufacturing and storage, making them a possible "off-the-shelf" therapy option.

The research team is now focusing on refining the manufacturing process and conducting safety studies in preparation for clinical trials.